In tumor settings, T cells could experience a phenotypic shift to terminal differentiation characterized by expressing KLRG-1 and CD57 but loss of CD28 after persistent exposure to neoantigen, which is termed “T-cell senescence” (12). The gene discussed is CD28; the disease is neoplasm.